Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Piramal Enterprises Limited is currently engaged in the patent prosecution process within the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action, which is being handled within 1 distinct art unit. This indicates a very specific technical focus for the company's current filings, with no other active matters currently distributed across different biotechnology-related art units. The 1 distinct art units involved suggest that the company's innovations are being scrutinized by a single specialized group at the USPTO.
The prosecution is managed by 1 distinct examiners, with CHONG, YONG SOO identified as the busiest examiner. CHONG, YONG SOO is responsible for 1 busiest examiner pending office action, representing the entirety of the company's active workload. This singular examiner assignment creates a direct relationship for negotiation and response during the prosecution of the company's biotechnology innovations. Having 1 pending office action and 1 distinct examiners simplifies the strategic planning for the portfolio, as there is no need to coordinate between different examiner preferences.
Practitioners can focus exclusively on the requirements and examination style of CHONG, YONG SOO within the Biotechnology & Pharmaceuticals field. This focused approach minimizes the need for multi-examiner coordination and allows for a concentrated effort on the 1 distinct art units involved. With 1 busiest examiner pending, the applicant can anticipate a consistent review process for their current filing. The 1 distinct examiners currently assigned ensures that the company's intellectual property strategy remains unified and focused on its core biotechnology objectives.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHONG, YONG SOO | 1 | 43.8% | +41.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18780771 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | CHONG, YONG SOO | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18780771 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | CHONG, YONG SOO | 1623 | DP | Non-Final OA | — | Pending | Jul 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPiramal Enterprises Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Yong Soo Chong has the most, with 1 of Piramal Enterprises Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
